FDA-Cleared Blood Test for Alzheimer’s Assessment in Primary Care Now Available Nationwide
The Elecsys pTau-181 test helps primary care clinicians rule out Alzheimer's disease in symptomatic patients aged 55 and older.
The Elecsys pTau-181 test helps primary care clinicians rule out Alzheimer's disease in symptomatic patients aged 55 and older.
Vanderbilt Medical Laboratories has implemented in-house rapid antigen testing for histoplasmosis, reducing turnaround times and improving patient management, according to clinical staff and recent case reports.
A longitudinal study finds blood-based biomarkers more sensitive than PET scans in detecting obesity's impact on Alzheimer's pathology.
Valley Diagnostics has secured exclusive global rights to develop point-of-care lateral flow tests for prostate cancer, lung cancer, and animal diseases, with product rollout planned for 2026.
University Hospital Southampton is trialing a point-of-care biosensor test for flu, COVID-19, and RSV, delivering results in four minutes, according to the hospital.
BillionToOne has partnered with Epic to integrate its UNITY Complete prenatal and Northstar oncology tests into Epic’s EHR system, enabling direct ordering and results delivery for healthcare providers.
The test is being developed to differentiate between adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis at the point of care.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
A large-scale international trial is evaluating a finger prick blood test for Alzheimer’s, analyzing three protein biomarkers as a potential alternative to PET scans and lumbar punctures.
HistoIndex and Houston Research Institute have partnered to offer AI-driven pathology analysis for metabolic dysfunction-associated steatohepatitis across four HRI centers in Texas, expanding advanced diagnostic services for liver disease.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The eight-minute test also shortened hospital stays by nearly two days at Froedtert Hospital, reinforcing previous multi-site evidence.